Chen Qing-yong, Lin Xian-ming, Zhou Jian-ying, An Zhou, Yang Ling, Jiang Zhong-yong
Department of Respiratory Medicine, 117th Hospital of People's Liberation Army, Hangzhou 310013, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2004 Feb;27(2):101-4.
To observe the relationship between levels of KAI1/CD82 and CD44 in lung carcinomas and their clinicopathological features, in association with the results of metastasis.
The expressions of KAI1/CD82 and CD44 in 45 patients with lung cancer were detected by flow-cytometry. Tissue samples 3 cm (control group 1) and 5 cm (control group 2) from the cancerous lesions and benign lesions from 30 patients (control group 3) were also studied, and the results were compared.
The expression level of KAI1/CD82 protein in lung cancer was lower than that in other three groups (P < 0.01), while the expression level of CD44 was higher than that in other three groups (P < 0.01). The expression level of KAI1/CD82 in control group 1 was also lower than that in control group 2 and benign lesion group (P < 0.05). The expression level of CD44 was higher than that in control group 2 and benign lesion group (P < 0.05). There was no significant difference between the expression level of CD44 and KAI1/CD82 in control group 2 and benign lesion group (P > 0.05). The expression level of KAI1/CD82 and CD44 were closely correlated with clinical staging, pathological differentiation and lymph node metastasis (P < 0.01), but their expressions were not correlated with sex, age, tumor size and pathological type (P > 0.05). Statistic difference was found between KAI1/CD82 and CD44 in primary lesions and metastatic lesions (P < 0.01). There was an inversely correlation between the expression of CD44 and KAI1/CD82 in clinical staging and lymph node metastasis (P < 0.01).
KAI1/CD82 and CD44 may play an important regulating role in the genesis, development and metastasis of lung cancer, and they may be used as potential markers for tumor metastasis.
观察肺癌组织中KAI1/CD82和CD44水平与其临床病理特征的关系，并结合转移结果进行分析。
采用流式细胞术检测45例肺癌患者KAI1/CD82和CD44的表达情况。同时研究30例患者癌灶3 cm处组织样本（对照组1）、5 cm处组织样本（对照组2）及良性病变组织样本（对照组3），并比较结果。
肺癌组织中KAI1/CD82蛋白表达水平低于其他三组（P < 0.01），而CD44表达水平高于其他三组（P < 0.01）。对照组1中KAI1/CD82表达水平也低于对照组2和良性病变组（P < 0.05）。CD44表达水平高于对照组2和良性病变组（P < 0.05）。对照组2和良性病变组中CD44与KAI1/CD82表达水平差异无统计学意义（P > 0.05）。KAI1/CD82和CD44表达水平与临床分期、病理分化及淋巴结转移密切相关（P < 0.01），但与性别、年龄、肿瘤大小及病理类型无关（P > 0.05）。原发灶与转移灶中KAI1/CD82和CD44存在统计学差异（P < 0.01）。临床分期及淋巴结转移中CD44与KAI1/CD82表达呈负相关（P < 0.01）。
KAI1/CD82和CD44可能在肺癌的发生、发展及转移中起重要调节作用，可作为肿瘤转移的潜在标志物。
